CAR-T细胞治疗B细胞淋巴瘤的十年结局
该研究报告38例复发或难治性B细胞非霍奇金淋巴瘤患者接受tisagenlecleucel输注后的长期随访结果,中位随访10.1年,未观察到5.4年后的复发,10年无淋巴瘤生存率在大B细胞淋巴瘤中为32%,在滤泡性淋巴瘤中为47%。
要点
- 10年无淋巴瘤生存率:大B细胞淋巴瘤32%,滤泡性淋巴瘤47%
- 5.4年后未再出现淋巴瘤复发
- 第二原发肿瘤10年累积发生率为21%
核心结论
- 对重度预处理B细胞非霍奇金淋巴瘤患者,单次tisagenlecleucel输注可使约三分之一的大B细胞淋巴瘤患者和近一半的滤泡性淋巴瘤患者获得十年期无淋巴瘤生存。
研究设计与样本
- 评估38例复发或难治性B细胞非霍奇金淋巴瘤患者(24例大B细胞淋巴瘤,14例滤泡性淋巴瘤)接受CTL019(现称tisagenlecleucel)治疗的长期结局。
- 无淋巴瘤生存定义为从tisagenlecleucel输注至复发或淋巴瘤相关死亡的时间。
- 非复发相关死亡和第二原发癌的发生率采用Aalen-Johansen方法估计,数据截止日期为2025年10月1日。
主要发现
- 中位随访10.1年(范围7.9至11.5),5.4年后未再发生淋巴瘤复发。
- 10年无淋巴瘤生存率在大B细胞淋巴瘤中为32%(95%CI 14至51),在滤泡性淋巴瘤中为47%(95%CI 20至71)。
- 10年无进展生存率(包含任何原因死亡)在大B细胞淋巴瘤中为17%(95%CI 5至34),在滤泡性淋巴瘤中为29%(95%CI 9至52)。
- 10年总生存率在大B细胞淋巴瘤中为17%(95%CI 5至34),在滤泡性淋巴瘤中为50%(95%CI 23至72)。
- 持续2级或3级中性粒细胞减少发生于2例患者(5%),未观察到晚期贫血或血小板减少;9例患者发生第二原发癌(10年累积发生率21%)。
关键数值与推荐
- 10年非复发相关死亡率为18%(排除COVID-19相关死亡后为14%)。
- 较高的CAR转基因持久性似乎与长期缓解相关;在长期缓解患者中,44%存在持续性B细胞发育不全。
临床怎么用
- tisagenlecleucel单次输注可为部分复发或难治性B细胞非霍奇金淋巴瘤患者带来十年期无淋巴瘤生存。
- 长期随访中需关注第二原发癌和非复发相关死亡风险。
局限性
- 样本量较小(共38例患者)。
- 长期缓解与CAR转基因持久性的关联为观察性发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a standard treatment for relapsed or refractory B-cell non-Hodgkin lymphomas. Long-term results and curative potential remain uncertain. METHODS: We evaluated long-term outcomes in 38 patients with relapsed or refractory B-cell non-Hodgkin lymphomas (24 patients with large B-cell lymphoma and 14 with follicular lymphoma) who had been treated with CTL019 (now called tisagenlecleucel) - autologous T cells expressing CD19-directed, 4-1BB-costimulated chimeric receptors. Lymphoma-free survival was defined as the time from the tisagenlecleucel infusion to relapse or lymphoma-related death. The incidence of non-relapse-related death and second primary cancer was estimated with the Aalen-Johansen method. The data-cutoff date was October 1, 2025. RESULTS: At a median follow-up of 10.1 years (range, 7.9 to 11.5), no relapses had occurred beyond 5.4 years. The 10-year lymphoma-free survival was 32% (95% confidence interval [CI], 14 to 51) among patients with large B-cell lymphoma and 47% (95% CI, 20 to 71) among those with follicular lymphoma. In an analysis that included deaths from any cause, the 10-year progression-free survival was 17% (95% CI, 5 to 34) among patients with large B-cell lymphoma and 29% (95% CI, 9 to 52) among those with follicular lymphoma; the 10-year overall survival was 17% (95% CI, 5 to 34) and 50% (95% CI, 23 to 72), respectively. Persistent grade 2 or 3 neutropenia occurred in 2 patients (5%); no late anemia or thrombocytopenia was observed. A second primary cancer developed in 9 patients (10-year cumulative incidence, 21%). The 10-year non-relapse-related mortality was 18% (14% when deaths related to coronavirus disease 2019 were excluded). Higher CAR-transgene persistence appeared to be associated with long-term response. B-cell aplasia persisted in 44% of patients with a long-term response. CONCLUSIONS: Among patients with heavily pretreated B-cell non-Hodgkin lymphoma, a single infusion of tisagenlecleucel led to decade-long remissions (lymphoma-free survival) in approximately one third of the patients with large B-cell lymphomas and in nearly one half of those with follicular lymphoma. (Funded by the Richard Berman Family Innovations Center in CLL and Lymphomas and others; ClinicalTrials.gov number, NCT02030834.).
引用
- Ruella M, Paruzzo L, Chong ER, et al. Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas. N Engl J Med. 2026. PMID: 42341302. doi:10.1056/NEJMoa2518035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。